PRCT

PROCEPT Biorobotics Corp (PRCT) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. PROCEPT Biorobotics Corporation develops and sells the AquaBeam and HYDROS robotic systems for the treatment of benign prostatic hyperplasia (BPH) using Aquablation therapy. As of June 30, 2025, the company reported a global install base of 762 robotic systems, including 595 in the United States. The company received FDA 510(k) clearance for its next-generation HYDROS Robotic System in August 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 48% year-over-year in Q2 and 52% year-over-year for the six-month period. Growth was driven by higher sales of systems, handpieces, and service contracts, with U.S. revenue accounting for 88% of total revenue.
• Margin Expansion: Gross margin improved to 65% from 59% in the prior year quarter, attributed to increased unit sales spreading fixed manufacturing overhead and higher average selling prices.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 38% year-over-year in Q2 ($56.3 million vs. $40.8 million) due to expanded commercial organization and stock-based compensation. R&D expenses remained relatively flat, increasing only 1%.
• Debt Restructuring: In August 2025 (subsequent to period end), the company amended its term loan facility. The repayment terms were modified so the entire principal is due at maturity (October 2027) rather than monthly amortization. Additionally, minimum cash holding requirements at the lender (CIBC) were adjusted.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash ($302.7 million) and anticipated revenue are sufficient to fund operations for at least the next 12 months.
• Strategic Focus: The company is focused on growing its install base (targeting ~2,700 U.S. hospitals) and increasing system utilization to drive recurring revenue from consumables.
• Regulatory & Tax: New federal tax legislation enacted in July 2025 affects R&D deductibility; management preliminarily assesses no material impact due to existing valuation allowances on deferred tax assets.
• Leadership Changes: The position of Chief Commercial Officer was eliminated in August 2025, with roles split into Senior Vice President of Sales and Senior Vice President of Marketing. Hisham Shiblaq is separating from the company effective September 1, 2025.
• Risks: Key risks include reimbursement decisions by third-party payors, competition, and the ability to scale manufacturing efficiently. The company has no material pending legal proceedings.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the amended loan facility covenants, specifically the minimum cash balance requirements at CIBC and the revenue/growth covenants if cash falls below $100 million.
• Install Base Utilization: Monitor the rate of system utilization and the conversion of hospital-based resective BPH procedures to Aquablation therapy to validate recurring revenue growth.
• Reimbursement Landscape: Track commercial payor coverage decisions outside of Medicare, as this is a critical driver for hospital adoption.
• Stock-Based Compensation: Review the impact of increasing stock-based compensation ($22.3 million YTD 2025) on future operating expenses and cash burn.
• Leadership Transition: Assess the impact of the Chief Commercial Officer departure and the restructuring of the sales and marketing leadership on commercial execution.